TORC2 Structure and Function
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The target of rapamycin (TOR) kinase functions in two multiprotein complexes, TORC1 and TORC2. Although both complexes are evolutionarily conserved, only TORC1 is acutely inhibited by rapamycin. Consequently, only TORC1 signaling is relatively well understood; and, at present, only mammalian TORC1 is a validated drug target, pursued in immunosuppression and oncology. However, the knowledge void surrounding TORC2 is dissipating. Acute inhibition of TORC2 with small molecules is now possible and structural studies of both TORC1 and TORC2 have recently been reported. Here we review these recent advances as well as observations made from tissue-specific mTORC2 knockout mice. Together these studies help define TORC2 structure-function relationships and suggest that mammalian TORC2 may one day also become a bona fide clinical target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 5×
“Emerging evidence suggests that MTORC2 may also be regulated by GTPases.”
BackgroundInfluentialSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886 · cited 2×
“Lst8 is composed entirely of WD40 repeats, which fold into a Glossary AGC kinase: a family of approximately 60 related protein kinases named after protein kinase A, protein kinase G, and protein kinase C.”
BackgroundSelf-citationA new bioinformatics analysis tools framework at EMBL-EBI
Goujon, M., McWilliam, H., Li, W., Valentin, F., Squizzato, S., Paern, J., & Lopez, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq313 · Cited by 1,846 · cited 2×
“They possess a conserved domain shared with the Aspergillus nidulans protein HbrB (Figure 1E) [45,46].”
BackgroundThe growing landscape of lysine acetylation links metabolism and cell signalling
Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., & Mann, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3841 · Cited by 1,324 · cited 1×
“The acetylation capacity of a cell is thought to be linked to metabolic status [68].”
BackgroundThe nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294 · cited 1×
“TORC2 Effectors The best characterized substrates of yeast and mammalian TORC2 are the AGC family kinases, which are activated downstream of TORC2 by phosphorylation on the so-called turn and hydrophobic motifs found in their C termini [78].”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · cited 2×
“DEPTOR interferes with the signaling output of the two [4_TD$DIFF] MTOR complexes through unknown mechanisms [48].”
BackgroundRapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
CDD: a Conserved Domain Database for protein classification
Marchler-Bauer, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki069 · Cited by 1,156 · cited 1×
“These domains are typically found N-terminal to the catalytic domain of RAS guanine nucleotide exchange factors but their specific function is unknown [28].”
BackgroundmTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075
García-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907
Bentzinger, C. F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J. B., Oliveri, F., Xia, J., Casanova, E., Costa, C. F., Brink, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.002 · Cited by 640 · cited 1×
“While in another study [89], [10_TD$DIFF]RICTOR-deficient muscle was indistinguishable from wild-type controls, although one should note that the ex vivo analyses of [10_TD$DIFF] RICTOR-deficient muscle was relatively less rigorous in this study.”
ResultRapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531 · cited 1×
“Indeed, some of the undesirable side effects of prolonged rapamycin treatment, including impaired sugar metabolism, are attributed to inhibition of MTORC2, although these might be mitigated with optimized treatment regimens [104,105].”
BackgroundArchitecture of human mTOR complex 1
Aylett, C. H. S., Sauer, E., Imseng, S., Boehringer, D., Hall, M. N., Ban, N., & Maier, T. (2016) · Science · doi:10.1126/science.aaa3870 · Cited by 344
Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size
Saci, A., Cantley, L. C., & Carpenter, C. L. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.017 · Cited by 275
Arriola Apelo, S. I., Neuman, J. C., Baar, E. L., Syed, F. A., Cummings, N. E., Brar, H. K., Pumper, C. P., Kimple, M. E., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12405 · Cited by 182 · cited 1×
“Indeed, some of the undesirable side effects of prolonged rapamycin treatment, including impaired sugar metabolism, are attributed to inhibition of MTORC2, although these might be mitigated with optimized treatment regimens [104,105].”
Background
Cited by
mTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
The regulation of autophagy by calcium signals: Do we have a consensus?
Bootman, M. D., Chehab, T., Bultynck, G., Parys, J. B., & Rietdorf, K. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.08.005 · Cited by 271
MTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266
“…other links from mTORC1 to the activation of protein synthesis and to the production of ribosomes 9,10 . mTORC2 has distinct substrates from mTORC1 11 , which include AKT (PKB) 12 , a protein kinase that is involved in anabolic signaling (for example, in the activation of mTORC1 13–15 and in cell…”
BackgroundJohnston, E. J., Moses, T., & Rosser, S. J. (2020) · Yeast · doi:10.1002/yea.3452 · Cited by 74
Metadata
- Authors
- Gaubitz, C., Prouteau, M., Kusmider, B., & Loewith, R.
- Venue
- Trends in Biochemical Sciences
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 41
- Issue
- 6
- Pages
- 532-545
- ISSN
- 0968-0004 (ISSN-L)
- OpenAlex
- W2345462336
- Cited by
- 164
- References
- 17
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.